Company Filing History:
Years Active: 2020
Title: Innovations of Gilles Voit in Cancer Imaging
Introduction
Gilles Voit is a notable inventor based in Dijon, France. He has made significant contributions to the field of cancer imaging through his innovative work on radiolabeled compounds. His research focuses on enhancing the diagnosis and treatment of various cancers influenced by epidermal growth factor receptors (EGFR).
Latest Patents
Gilles Voit holds a patent for a "Radiolabeled macrocyclic EGFR inhibitor." This invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which serve as positron emission tomography (PET) tracers for imaging EGFR. The patent outlines their application in in vivo diagnosis, preclinical and clinical tumor imaging, and patient stratification based on the mutational status of EGFR. It also discusses methods for preparing these radiotracers and their relevance to various cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer.
Career Highlights
Gilles Voit is associated with Oncodesign SA, a company dedicated to advancing cancer treatment through innovative technologies. His work has been pivotal in developing new diagnostic tools that can significantly improve patient outcomes.
Collaborations
Gilles Voit collaborates with esteemed colleagues such as Jan Marie Cyriel Jozef Hoflack and Cyril Berthet. Their combined expertise contributes to the advancement of cancer research and the development of effective diagnostic methods.
Conclusion
Gilles Voit's contributions to cancer imaging through his patented innovations highlight the importance of research in improving diagnostic techniques. His work continues to pave the way for advancements in the treatment of various cancers.